CIC De Novo Loss of Function Variants Contribute to Cerebral Folate Deficiency by Downregulating FOLR1 Expression Xuanye Cao,1 Annika Wolf,2 Sung-­Eun Kim,3 Robert M

Total Page:16

File Type:pdf, Size:1020Kb

CIC De Novo Loss of Function Variants Contribute to Cerebral Folate Deficiency by Downregulating FOLR1 Expression Xuanye Cao,1 Annika Wolf,2 Sung-­Eun Kim,3 Robert M Neurogenetics J Med Genet: first published as 10.1136/jmedgenet-2020-106987 on 20 August 2020. Downloaded from Original research CIC de novo loss of function variants contribute to cerebral folate deficiency by downregulating FOLR1 expression Xuanye Cao,1 Annika Wolf,2 Sung- Eun Kim,3 Robert M. Cabrera,1 Bogdan J. Wlodarczyk,1 Huiping Zhu,4 Margaret Parker,3 Ying Lin,1 John W. Steele,1,5 Xiao Han,1 Vincent Th Ramaekers ,6 Robert Steinfeld,2,7 Richard H. Finnell,3,8,9 Yunping Lei 1 2 ► Additional material is ABSTRact epilepsy, ataxia and pyramidal tract signs. Folate is published online only. To view Background Cerebral folate deficiency (CFD) absorbed into the bloodstream via the gastrointes- please visit the journal online (http:// dx. doi. org/ 10. 1136/ syndrome is characterised by a low concentration of tinal tract mainly through two uptake systems: the jmedgenet- 2020- 106987). 5- methyltetrahydrofolate in cerebrospinal fluid, while reduced folate carrier 1 (RFC1; SLC19A1) and the folate levels in plasma and red blood cells are in the low proton- coupled folate transporter (PCFT).3 From For numbered affiliations see normal range. Mutations in several folate pathway genes, the bloodstream, folate binds to the folate receptor end of article. including FOLR1 (folate receptor alpha, FRα), DHFR alpha (FRα/FOLR1) on the basolateral endothelial (dihydrofolate reductase) and PCFT (proton coupled surface of the choroid plexus. Through receptor- Correspondence to Dr. Yunping Lei, Baylor College folate transporter) have been previously identified in mediated endocytosis and transcytosis, folate is of Medicine, Houston, Texas, patients with CFD. then transported across the blood- CSF- barrier USA; yunpinglei@ gmail. com Methods In an effort to identify causal mutations for into the CSF.4 FOLR1 is highly expressed in the Dr. Richard H. Finnell; CFD, we performed whole exome sequencing analysis on choroid plexus, and it has a higher affinity to folic richard. finnell@ bcm. edu eight CFD trios and identified eight de novo mutations in Dr. Robert Steinfeld; acid (FA) at neutral pH compared with other folate 5 Robert. Steinfeld@ kispi. uzh. ch seven trios. transporters, such as PCFT and RFC1. These two Results Notably, we found a de novo stop gain characteristics are important factors in building and XC, AW and S- EK contributed mutation in the capicua (CIC) gene. Using 48 sporadic keeping higher folate concentrations in the CSF equally. CFD samples as a validation cohort, we identified than in serum. Previous studies demonstrated that Received 10 March 2020 three additional rare variants in CIC that are putatively dysfunctional FOLR1, such as that which could be Revised 27 May 2020 deleterious mutations. Functional analysis indicates that the result of either FOLR1 mutations6 7 or FOLR1 Accepted 5 June 2020 CIC binds to an octameric sequence in the promoter autoantibodies,8 can result in CFD. Mutations in Published Online First 20 August regions of folate transport genes: FOLR1, PCFT and 9 10 http://jmg.bmj.com/ 2020 other folate related genes, such as DHFR and reduced folate carrier (Slc19A1; RFC1). The CIC nonsense PCFT,11 12 are also reported to be associated with variant (p.R353X) downregulated FOLR1 expression in low 5- MTHF CSF concentrations. We previously HeLa cells as well as in the induced pluripotent stem cell reported a patient carrying a de novo truncating (iPSCs) derived from the original CFD proband. Folate CIC mutation.13 The patient presented with a paedi- binding assay demonstrated that the p.R353X variant atric B- cell acute lymphoblastic leukaemia (B- ALL) decreased cellular binding of folic acid in cells. and was treated with methotrexate (MTX). She Conclusion This study indicates that CIC loss of function on September 29, 2021 by guest. Protected copyright. developed a spectrum of neurobehavioral disor- variants can contribute to the genetic aetiology of ders including signs of autistic spectrum disorder, CFD through regulating FOLR1 expression. Our study seizures, loss of language and motor skills and had described the first mutations in a non- folate pathway CFD, even after cancer remission and the discontin- gene that can contribute to the aetiology of CFD. uation of MTX treatment. The CIC gene was originally discovered in Drosophila, where it was shown to be highly 14 INTRODUCTION expressed in the head and tail region, which Cerebral folate deficiency (CFD) is defined as resulted in the naming of it ‘head and tail’ or any neurological syndrome associated with low ‘capicua’ in Catalan. It is a transcriptional repressor 5- methyltetrahydrofolate (5- MTHF) concentra- of the high mobility group (HMG)- box family, tions in cerebrospinal fluid (CSF), while folate which binds a specific octameric DNA sequence, © Author(s) (or their T(G/C)AATG(A/G)A, in the genome via their employer(s)) 2021. Re-use concentrations in serum are typically in the low 1 15 permitted under CC BY-NC . No normal range. In humans, the folate concentration HMG- box and C1 domain. CIC is known to be commercial re-use . See rights in the CSF is normally ≥1.5- fold higher than in transported into the nucleus by KPNA3, a nuclear and permissions. Published serum. As folate is essential for normal development importin protein that can interact with CIC at its by BMJ. and production of the biogenic amines and pterins C- terminal nuclear localisation signal domain.16 To cite: Cao X, Wolf A, in the central nervous system, prenatal and post- It was found to function downstream of the EGF- Kim S- E, et al. J Med Genet natal folate deficiency produces a variety of neuro- RTK- RAS- ERK- MAPK signalling pathway to 2021;58:484–494. logical symptoms, including intellectual disability, control embryonic pattern formation.14 Recently, 484 Cao X, et al. J Med Genet 2021;58:484–494. doi:10.1136/jmedgenet-2020-106987 Neurogenetics J Med Genet: first published as 10.1136/jmedgenet-2020-106987 on 20 August 2020. Downloaded from studies also indicated CIC influences Toll/Interleukin-1 signal- Sequencing analysis of DNA samples ling.17 The most well- known CIC downstream target genes DNA sequencing libraries were built using NEBNext Ultra include polyomavirus enhancer activator 3 family members DNA Library Prep Kit (New England Biolabs) following proto- genes, ETV1, ETV4 and ETV5 as well as matrix metalloproteinase cols as described by the manufacturer (V.3.0). The Agilent Sure- 9 (MMP9)18 and MMP24.19 In the absence of EGFR-ERK signal- Select Human All Exon V5 (Agilent Technologies) was used for ling, CIC binds to and represses those genes, while activation of exome enrichment. Libraries were sequenced by the Genome the pathway results in inactivation of CIC through phosphor- Sequencing and Analysis Facility at University of Texas at ylation induced degradation or relocalisation from the nucleus Austin using an Illumina Hi- Seq 2000 platform (Illumina). to the cytoplasm.20–23 In mammals, CIC forms a transcriptional Next generation sequencing data were analysed following repressor complex with ataxin-1, a gene that contributes to the GATK Best Practices (https:// software. broadinstitute. org/ gatk/ pathogenesis of spinocerebellar ataxia type 1.24 Conventional best- practices/). Briefly, FASTQ format data were mapped to 29 Cic knockout (KO) mice present with omphalocele, abnormally hg19 using BWA alignment software, sorted and indexed by 30 31 small litter size and lung differentiation defects that result in SAMtools, base recalibrated by GATK and duplicate reads perinatal lethality.18 25 In early development, mice with a condi- removed by Picard software (https:// broadinstitute. github. tional CIC KO display impaired forebrain neurodevelopment, io/ picard/). Variants were called using GATK Haplotype- resulting in hyperactivity, decreased learning ability and impaired Caller methods. De novo variant analysis was performed by 32 memory.13 In adult mice, systemic conditional CIC inactivation TrioDeNovo software. Variants annotation was performed 33 induces T- cell acute lymphoblastic lymphoma. CIC was also with Annovar. Sanger sequencing was performed following 34 reported to modify peripheral immune tolerance by suppressing previously published primers and protocols. CIC sequencing aberrant activation of adaptive immunity.26 In humans, CIC primers are in online supplementary table 1. Polyphen2, SIFT mutations have been associated with several diseases, including and CADD scores were used for predicting variants’ func- 35–37 neurobehavioral phenotypes,13 oligodendroglioma,27 lung carci- tion. The gnomAD database was used for examining the 38 noma19 and prostate cancer.28 allele frequency of each mutants. Although studies have reported that mutations in human CIC are strongly associated with ALL and neurobehavioral pheno- Plasmid preparation and siRNA information types, studies to date have failed to determine whether CIC GFP- CIC and HA- KPNA3 plasmids were provided to us by Dr mutations contribute to the aetiology of CFD. In fact, there are Carol MacKintosh at the University of Dundee. CIC variant no comprehensive trio- based genetic studies on patients with was introduced into the GFP- CIC plasmid using the GeneArt CFD. Since the aforementioned patient who carries the trun- Site- Directed Mutagenesis System (Cat# A14604, Thermofisher cated CIC mutation does not seem to carry any rare variant in Scientific). Ataxin-1 plasmids were provided by Dr Huda Zoghbi known CFD genes (FOLR1, PCFT and RFC1) in our whole at Baylor College of Medicine (Addgene Cat# 48189). exome sequencing (WES) dataset, we propose that the truncated Full-length human CIC and CIC variant were inserted via CIC protein may play a role in CFD progression. Thus, CFD EcoRI/SalI into the expression vector pLVX-IRES- puro (Takara may be caused from genetic factors other than variants in known Bio) containing an EGFP ORF. Vectors for production of lentiviral folate transport genes. In order to better understand the aeti- particles pMD2.G and psPAX2 were from Addgene (plasmids ology of CFD, a comprehensive genetic profiling of patients with Cat# 12259, Cat# 12260; deposited by Didier Trono).
Recommended publications
  • Regulates Cellular Telomerase Activity by Methylation of TERT Promoter
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 5), pp: 7977-7988 Research Paper Tianshengyuan-1 (TSY-1) regulates cellular Telomerase activity by methylation of TERT promoter Weibo Yu1, Xiaotian Qin2, Yusheng Jin1, Yawei Li2, Chintda Santiskulvong3, Victor Vu1, Gang Zeng4,5, Zuofeng Zhang6, Michelle Chow1, Jianyu Rao1,5 1Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA 2Beijing Boyuantaihe Biological Technology Co., Ltd., Beijing, China 3Genomics Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA 4Department of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA 5Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA, USA 6Department of Epidemiology, School of Public Health, University of California at Los Angeles, Los Angeles, CA, USA Correspondence to: Jianyu Rao, email: [email protected] Keywords: TSY-1, hematopoietic cells, Telomerase, TERT, methylation Received: September 08, 2016 Accepted: November 24, 2016 Published: December 15, 2016 ABSTRACT Telomere and Telomerase have recently been explored as anti-aging and anti- cancer drug targets with only limited success. Previously we showed that the Chinese herbal medicine Tianshengyuan-1 (TSY-1), an agent used to treat bone marrow deficiency, has a profound effect on stimulating Telomerase activity in hematopoietic cells. Here, the mechanism of TSY-1 on cellular Telomerase activity was further investigated using HL60, a promyelocytic leukemia cell line, normal peripheral blood mononuclear cells, and CD34+ hematopoietic stem cells derived from umbilical cord blood. TSY-1 increases Telomerase activity in normal peripheral blood mononuclear cells and CD34+ hematopoietic stem cells with innately low Telomerase activity but decreases Telomerase activity in HL60 cells with high intrinsic Telomerase activity, both in a dose-response manner.
    [Show full text]
  • A New Class of Disordered Elements Controls DNA Replication Through
    RESEARCH ARTICLE A new class of disordered elements controls DNA replication through initiator self-assembly Matthew W Parker1,2, Maren Bell2, Mustafa Mir2, Jonchee A Kao2, Xavier Darzacq2, Michael R Botchan2*, James M Berger1* 1Department of Biophysics and Biophysical Chemistry, Johns Hopkins School of Medicine, Baltimore, United States; 2Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States Abstract The initiation of DNA replication in metazoans occurs at thousands of chromosomal sites known as origins. At each origin, the Origin Recognition Complex (ORC), Cdc6, and Cdt1 co- assemble to load the Mcm2-7 replicative helicase onto chromatin. Current replication models envisage a linear arrangement of isolated origins functioning autonomously; the extent of inter- origin organization and communication is unknown. Here, we report that the replication initiation machinery of D. melanogaster unexpectedly undergoes liquid-liquid phase separation (LLPS) upon binding DNA in vitro. We find that ORC, Cdc6, and Cdt1 contain intrinsically disordered regions (IDRs) that drive LLPS and constitute a new class of phase separating elements. Initiator IDRs are shown to regulate multiple functions, including chromosome recruitment, initiator-specific co- assembly, and Mcm2-7 loading. These data help explain how CDK activity controls replication initiation and suggest that replication programs are subject to higher-order levels of inter-origin organization. DOI: https://doi.org/10.7554/eLife.48562.001 *For
    [Show full text]
  • Folate Receptor Alpha Defect Causes Cerebral Folate Transport Deficiency: a Treatable Neurodegenerative Disorder Associated with Disturbed Myelin Metabolism
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector ARTICLE Folate Receptor Alpha Defect Causes Cerebral Folate Transport Deficiency: A Treatable Neurodegenerative Disorder Associated with Disturbed Myelin Metabolism Robert Steinfeld,1,5,* Marcel Grapp,1,5 Ralph Kraetzner,1 Steffi Dreha-Kulaczewski,1 Gunther Helms,2 Peter Dechent,2 Ron Wevers,3 Salvatore Grosso,4 and Jutta Ga¨rtner1 Sufficient folate supplementation is essential for a multitude of biological processes and diverse organ systems. At least five distinct in- herited disorders of folate transport and metabolism are presently known, all of which cause systemic folate deficiency. We identified an inherited brain-specific folate transport defect that is caused by mutations in the folate receptor 1 (FOLR1) gene coding for folate receptor alpha (FRa). Three patients carrying FOLR1 mutations developed progressive movement disturbance, psychomotor decline, and epilepsy and showed severely reduced folate concentrations in the cerebrospinal fluid (CSF). Brain magnetic resonance imaging (MRI) demon- strated profound hypomyelination, and MR-based in vivo metabolite analysis indicated a combined depletion of white-matter choline and inositol. Retroviral transfection of patient cells with either FRa or FRb could rescue folate binding. Furthermore, CSF folate concen- trations, as well as glial choline and inositol depletion, were restored by folinic acid therapy and preceded clinical improvements. Our studies not only characterize
    [Show full text]
  • B Vitamin Polymorphisms and Behavior: Evidence of Associations
    G Model NBR 2010 1–14 ARTICLE IN PRESS Neuroscience and Biobehavioral Reviews xxx (2014) xxx–xxx Contents lists available at ScienceDirect Neuroscience and Biobehavioral Reviews jou rnal homepage: www.elsevier.com/locate/neubiorev 1 Review 2 B vitamin polymorphisms and behavior: Evidence of associations 3 with neurodevelopment, depression, schizophrenia, bipolar disorder 4 and cognitive decline ∗ 5 Q1 E. Siobhan Mitchell , Nelly Conus, Jim Kaput 6 Nestle Institute of Health Science, Innovation Park, EPFL Campus, Lausanne 1015, Switzerland 7 298 a r t i c l e i n f o a b s t r a c t 9 10 Article history: The B vitamins folic acid, vitamin B12 and B6 are essential for neuronal function, and severe deficiencies 11 Received 16 December 2013 have been linked to increased risk of neurodevelopmental disorders, psychiatric disease and dementia. 12 Received in revised form 11 July 2014 Polymorphisms of genes involved in B vitamin absorption, metabolism and function, such as methylene 13 Accepted 18 August 2014 tetrahydrofolate reductase (MTHFR), cystathionine ␤ synthase (C␤S), transcobalamin 2 receptor (TCN2) 14 Available online xxx and methionine synthase reductase (MTRR), have also been linked to increased incidence of psychiatric 15 and cognitive disorders. However, the effects of these polymorphisms are often quite small and many 16 Keywords: studies failed to show any meaningful or consistent associations. This review discusses previous findings 17 Folate from clinical studies and highlights gaps in knowledge. Future studies assessing B vitamin-associated 18 Vitamin B9 polymorphisms must take into account not just traditional demographics, but subjects’ overall diet, 19 Vitamin B12 20 Vitamin B6 relevant biomarkers of nutritional status and also analyze related genetic factors that may exacerbate 21 Dementia behavioral effects or nutritional status.
    [Show full text]
  • Supplementary Table S1. Correlation Between the Mutant P53-Interacting Partners and PTTG3P, PTTG1 and PTTG2, Based on Data from Starbase V3.0 Database
    Supplementary Table S1. Correlation between the mutant p53-interacting partners and PTTG3P, PTTG1 and PTTG2, based on data from StarBase v3.0 database. PTTG3P PTTG1 PTTG2 Gene ID Coefficient-R p-value Coefficient-R p-value Coefficient-R p-value NF-YA ENSG00000001167 −0.077 8.59e-2 −0.210 2.09e-6 −0.122 6.23e-3 NF-YB ENSG00000120837 0.176 7.12e-5 0.227 2.82e-7 0.094 3.59e-2 NF-YC ENSG00000066136 0.124 5.45e-3 0.124 5.40e-3 0.051 2.51e-1 Sp1 ENSG00000185591 −0.014 7.50e-1 −0.201 5.82e-6 −0.072 1.07e-1 Ets-1 ENSG00000134954 −0.096 3.14e-2 −0.257 4.83e-9 0.034 4.46e-1 VDR ENSG00000111424 −0.091 4.10e-2 −0.216 1.03e-6 0.014 7.48e-1 SREBP-2 ENSG00000198911 −0.064 1.53e-1 −0.147 9.27e-4 −0.073 1.01e-1 TopBP1 ENSG00000163781 0.067 1.36e-1 0.051 2.57e-1 −0.020 6.57e-1 Pin1 ENSG00000127445 0.250 1.40e-8 0.571 9.56e-45 0.187 2.52e-5 MRE11 ENSG00000020922 0.063 1.56e-1 −0.007 8.81e-1 −0.024 5.93e-1 PML ENSG00000140464 0.072 1.05e-1 0.217 9.36e-7 0.166 1.85e-4 p63 ENSG00000073282 −0.120 7.04e-3 −0.283 1.08e-10 −0.198 7.71e-6 p73 ENSG00000078900 0.104 2.03e-2 0.258 4.67e-9 0.097 3.02e-2 Supplementary Table S2.
    [Show full text]
  • (FOLR1) Mrna Expression, Its Specific Promoter
    Notaro et al. BMC Cancer (2016) 16:589 DOI 10.1186/s12885-016-2637-y RESEARCH ARTICLE Open Access Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers Sara Notaro1,2, Daniel Reimer1, Heidi Fiegl1, Gabriel Schmid1, Annamarie Wiedemair1, Julia Rössler1, Christian Marth1 and Alain Gustave Zeimet1* Abstract Background: In this retrospective study we evaluated the respective correlations and clinical relevance of FOLR1 mRNA expression, FOLR1 promoter specific methylation and global DNA hypomethylation in type I and type II ovarian cancer. Methods: Two hundred fifty four ovarian cancers, 13 borderline tumours and 60 samples of healthy fallopian epithelium and normal ovarian epithelium were retrospectively analysed for FOLR1 expression with RT-PCR. FOLR1 DNA promoter methylation and global DNA hypomethylation (measured by means of LINE1 DNA hypomethylation) were evaluated with MethyLight technique. Results: No correlation between FOLR1 mRNA expression and its specific promoter DNA methylation was found neither in type I nor in type II cancers, however, high FOLR1 mRNA expression was found to be correlated with global DNA hypomethylation in type II cancers (p = 0.033). Strong FOLR1 mRNA expression was revealed for Grades 2-3, FIGO stages III-IV, residual disease > 0, and serous histotype. High FOLR1 expression was found to predict increased platinum sensitivity in type I cancers (odds ratio = 3.288; 1.256-10.75; p = 0.020). One-year survival analysis showed in type I cancers an independent better outcome for strong expression of FOLR1 in FIGO stage III and IV.
    [Show full text]
  • Arsenic Hexoxide Has Differential Effects on Cell Proliferation And
    www.nature.com/scientificreports OPEN Arsenic hexoxide has diferential efects on cell proliferation and genome‑wide gene expression in human primary mammary epithelial and MCF7 cells Donguk Kim1,7, Na Yeon Park2,7, Keunsoo Kang3, Stuart K. Calderwood4, Dong‑Hyung Cho2, Ill Ju Bae5* & Heeyoun Bunch1,6* Arsenic is reportedly a biphasic inorganic compound for its toxicity and anticancer efects in humans. Recent studies have shown that certain arsenic compounds including arsenic hexoxide (AS4O6; hereafter, AS6) induce programmed cell death and cell cycle arrest in human cancer cells and murine cancer models. However, the mechanisms by which AS6 suppresses cancer cells are incompletely understood. In this study, we report the mechanisms of AS6 through transcriptome analyses. In particular, the cytotoxicity and global gene expression regulation by AS6 were compared in human normal and cancer breast epithelial cells. Using RNA‑sequencing and bioinformatics analyses, diferentially expressed genes in signifcantly afected biological pathways in these cell types were validated by real‑time quantitative polymerase chain reaction and immunoblotting assays. Our data show markedly diferential efects of AS6 on cytotoxicity and gene expression in human mammary epithelial normal cells (HUMEC) and Michigan Cancer Foundation 7 (MCF7), a human mammary epithelial cancer cell line. AS6 selectively arrests cell growth and induces cell death in MCF7 cells without afecting the growth of HUMEC in a dose‑dependent manner. AS6 alters the transcription of a large number of genes in MCF7 cells, but much fewer genes in HUMEC. Importantly, we found that the cell proliferation, cell cycle, and DNA repair pathways are signifcantly suppressed whereas cellular stress response and apoptotic pathways increase in AS6‑treated MCF7 cells.
    [Show full text]
  • RFC1 Rabbit Pab
    Leader in Biomolecular Solutions for Life Science RFC1 Rabbit pAb Catalog No.: A1625 Basic Information Background Catalog No. This gene encodes the large subunit of replication factor C, a five subunit DNA A1625 polymerase accessory protein, which is a DNA-dependent ATPase required for eukaryotic DNA replication and repair. The large subunit acts as an activator of DNA Observed MW polymerases, binds to the 3' end of primers, and promotes coordinated synthesis of 140KDa both strands. It may also have a role in telomere stability. Alternatively spliced transcript variants encoding different isoforms have been noted for this gene. Calculated MW 128kDa Category Primary antibody Applications WB, IF Cross-Reactivity Human, Mouse, Rat Recommended Dilutions Immunogen Information WB 1:500 - 1:2000 Gene ID Swiss Prot 5981 P35251 IF 1:50 - 1:200 Immunogen Recombinant fusion protein containing a sequence corresponding to amino acids 400-700 of human RFC1 (NP_001191676.1). Synonyms RFC1;A1;MHCBFB;PO-GA;RECC1;RFC;RFC140 Contact Product Information www.abclonal.com Source Isotype Purification Rabbit IgG Affinity purification Storage Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide,50% glycerol,pH7.3. Validation Data Western blot analysis of extracts of various cell lines, using RFC1 antibody (A1625) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (AS014) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit (RM00020). Exposure time: 180s. Western blot analysis of extracts of HeLa cells, using RFC1 antibody (A1625) at 1:1000 dilution.
    [Show full text]
  • The Second Subunit of DNA Polymerase Delta Is Required for Genomic Stability and Epigenetic Regulation1[OPEN]
    The Second Subunit of DNA Polymerase Delta Is Required for Genomic Stability and Epigenetic Regulation1[OPEN] Jixiang Zhang, Shaojun Xie, Jinkui Cheng, Jinsheng Lai, Jian-Kang Zhu, and Zhizhong Gong* State Key Laboratory of Plant Physiology and Biochemistry, College of Biological Sciences, China Agricultural University, Beijing 100193, China (J.Z., J.C., Z.G.); Shanghai Center for Plant Stress Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200032, China (S.X., J.-K.Z.); Department of Horticulture and Landscape Architecture, Purdue University, West Lafayette, Indiana 47906 (S.X., J.-K.Z.); and State Key Laboratory of Agrobiotechnology, China National Maize Improvement Center, Department of Plant Genetics and Breeding, China Agricultural University, Beijing 100193, China (J.L.) ORCID IDs: 0000-0002-1641-8650 (J.Z.); 0000-0002-6719-9814 (S.X.); 0000-0001-5134-731X (J.-K.Z.). DNA polymerase d plays crucial roles in DNA repair and replication as well as maintaining genomic stability. However, the function of POLD2, the second small subunit of DNA polymerase d, has not been characterized yet in Arabidopsis (Arabidopsis thaliana). During a genetic screen for release of transcriptional gene silencing, we identified a mutation in POLD2. Whole-genome bisulfite sequencing indicated that POLD2 is not involved in the regulation of DNA methylation. POLD2 genetically interacts with Ataxia Telangiectasia-mutated and Rad3-related and DNA polymerase a. The pold2-1 mutant exhibits genomic instability with a high frequency of homologous recombination. It also exhibits hypersensitivity to DNA-damaging reagents and short telomere length. Whole-genome chromatin immunoprecipitation sequencing and RNA sequencing analyses suggest that pold2-1 changes H3K27me3 and H3K4me3 modifications, and these changes are correlated with the gene expression levels.
    [Show full text]
  • Novel Anti-FOLR1 Antibody–Drug Conjugate Morab-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells
    antibodies Article Novel Anti-FOLR1 Antibody–Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells Yuki Matsunaga 1, Toshimitsu Yamaoka 2,* , Motoi Ohba 2, Sakiko Miura 3, Hiroko Masuda 1, Takafumi Sangai 4 , Masafumi Takimoto 3, Seigo Nakamura 1 and Junji Tsurutani 2 1 Department of Breast Surgical Oncology, School of Medicine, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan; [email protected] (Y.M.); [email protected] (H.M.); [email protected] (S.N.) 2 Advanced Cancer Translational Research Institute, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan; [email protected] (M.O.); [email protected] (J.T.) 3 Department of Pathology, School of Medicine, Showa University, Tokyo 142-8666, Japan; [email protected] (S.M.); [email protected] (M.T.) 4 Department of Breast and Thyroid Surgery, School of Medicine, Kitasato University, Kanagawa 252-0375, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-3-3784-8146 Abstract: Antibody–drug conjugates (ADCs), which are currently being developed, may become promising cancer therapeutics. Folate receptor α (FOLR1), a glycosylphosphatidylinositol-anchored membrane protein, is an attractive target of ADCs, as it is largely absent from normal tissues but is overexpressed in malignant tumors of epithelial origin, including ovarian, lung, and breast cancer. In this study, we tested the effects of novel anti-FOLR1 antibody–eribulin conjugate MORAb-202 in breast cancer and non-small cell lung cancer (NSCLC) cell lines.
    [Show full text]
  • Control of Genome Integrity by RFC Complexes; Conductors of PCNA Loading Onto and Unloading from Chromatin During DNA Replication
    Review Control of Genome Integrity by RFC Complexes; Conductors of PCNA Loading onto and Unloading from Chromatin during DNA Replication Yasushi Shiomi *and Hideo Nishitani * Graduate School of Life Science, University of Hyogo, Kamigori, Ako‐gun, Hyogo 678‐1297, Japan Correspondence: [email protected]‐hyogo.ac.jp (Y.S.); [email protected]‐hyogo.ac.jp (H.N.) Academic Editor: Eishi Noguchi Received: 28 November 2016; Accepted: 21 January 2017; Published: 26 January 2017 Abstract: During cell division, genome integrity is maintained by faithful DNA replication during S phase, followed by accurate segregation in mitosis. Many DNA metabolic events linked with DNA replication are also regulated throughout the cell cycle. In eukaryotes, the DNA sliding clamp, proliferating cell nuclear antigen (PCNA), acts on chromatin as a processivity factor for DNA polymerases. Since its discovery, many other PCNA binding partners have been identified that function during DNA replication, repair, recombination, chromatin remodeling, cohesion, and proteolysis in cell‐cycle progression. PCNA not only recruits the proteins involved in such events, but it also actively controls their function as chromatin assembles. Therefore, control of PCNA‐loading onto chromatin is fundamental for various replication‐coupled reactions. PCNA is loaded onto chromatin by PCNA‐loading replication factor C (RFC) complexes. Both RFC1‐RFC and Ctf18‐RFC fundamentally function as PCNA loaders. On the other hand, after DNA synthesis, PCNA must be removed from chromatin by Elg1‐RFC. Functional defects in RFC complexes lead to chromosomal abnormalities. In this review, we summarize the structural and functional relationships among RFC complexes, and describe how the regulation of PCNA loading/unloading by RFC complexes contributes to maintaining genome integrity.
    [Show full text]
  • Characterization of the Repeat-Tract Instability and Mutator Phenotypes Conferred by a Tn3 Insertion in RFC1, the Large Subunit of the Yeast Clamp Loader
    Copyright 1999 by the Genetics Society of America Characterization of the Repeat-Tract Instability and Mutator Phenotypes Conferred by a Tn3 Insertion in RFC1, the Large Subunit of the Yeast Clamp Loader Yali Xie,* Chris Counter² and Eric Alani* *Section of Genetics and Development, Cornell University, Ithaca, New York 14853-2703 and ²Department of Pharmacology and Cancer Biology, Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710 Manuscript received August 3, 1998 Accepted for publication October 22, 1998 ABSTRACT The RFC1 gene encodes the large subunit of the yeast clamp loader (RFC) that is a component of eukaryotic DNA polymerase holoenzymes. We identi®ed a mutant allele of RFC1 (rfc1::Tn3) from a large collection of Saccharomyces cerevisiae mutants that were inviable when present in a rad52 null mutation background. Analysis of rfc1::Tn3 strains indicated that they displayed both a mutator and repeat-tract instability phenotype. Strains bearing this allele were characterized in combination with mismatch repair (msh2D, pms1D), double-strand break repair (rad52), and DNA replication (pol3-01, pol30-52, rth1D/rad27D) mutations in both forward mutation and repeat-tract instability assays. This analysis indicated that the rfc1::Tn3 allele displays synthetic lethality with pol30, pol3, and rad27 mutations. Measurement of forward mutation frequencies in msh2D rfc1:Tn3 and pms1D rfc1:Tn3 strains indicated that the rfc1::Tn3 mutant displayed a mutation frequency that appeared nearly multiplicative with the mutation frequency exhibited by mismatch-repair mutants. In repeat-tract instability assays, however, the rfc1::Tn3 mutant displayed a tract instability phenotype that appeared epistatic to the phenotype displayed by mismatch-repair mutants.
    [Show full text]